Open access
Sep 2026
852. Preclinical models of non dopaminergic antipsychotics
TAAR1 agonists provide a mechanistically distinct alternative to D2 antagonists, with potential advantages in tolerability and metabolic profile, and preclinical models support their relevance for symptom domains inadequately targeted by current therapies.
G. Rutigliano
· International Journal of Neu... · 0 citations